Prognosis of metastatic breast cancer subtypes: The hormone receptor/HER2-positive subtype is associated with the most favorable outcome

Breast Cancer Research and Treatment

Volumn 141, Issue 3, 2013, Pages 507-514

  Lobbezoo, Dorien J A ^a,b   Van Kampen, Roel J W ^a   Voogd, Adri C ^a   Dercksen, M Wouter ^b   Van Den Berkmortel, Franchette ^c   Smilde, Tineke J ^d   Van De Wouw, Agnes J ^e   Peters, Frank P J ^c   Van Riel, Johanna M G H ^f   Peters, Natascha A J B ^g   De Boer, Maaike ^a   Borm, George F ^h   Tjan Heijnen, Vivianne C G ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e VIECURI MEDICAL CENTER   (Netherlands)

^f CPRLab   (Netherlands)

^g Weert   (Netherlands)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Distant metastases; Prognosis; Subtypes; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; HORMONE RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SKIN METASTASIS; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2;

EID: 84887029181     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2711-y     Document Type: Article

References (27)

1. Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133-1144
2. Coates AS, Colleoni M, Goldhirsch A (2012) Is adjuvant chemotherapy useful for women with luminal a breast cancer? J Clin Oncol 30:1260-1263
3. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736-1747
4. Yamamoto N, Watanabe T, Katsumata N et al (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16:2401-2408
5. Insa A, Lluch A, Prosper F et al (1999) Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 56:67-78
6. Chang J, Clark GM, Allred DC et al (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97:545-553
7. Jung SY, Rosenzweig M, Sereika SM et al (2012) Factors associated with mortality after breast cancer metastasis. Cancer Causes Control 23:103-112
8. Largillier R, Ferrero JM, Doyen J et al (2008) Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 19:2012-2019
9. Beslija S, Bonneterre J, Burstein HJ et al (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20:1771-1785
10. Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271-3277
11. Dawood S, Broglio K, Buzdar AU et al (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92-98
12. Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual. Springer, New York
13. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410
14. Planchat E, Durando X, Abrial C et al (2011) Prognostic value of initial tumor parameters after metastatic relapse. Cancer Invest 29:635-643
15. Puente J, Lopez-Tarruella S, Ruiz A et al (2010) Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo register. Breast Cancer Res Treat 122:591-600
16. Chia S (2012) Testing for discordance at metastatic relapse: does it matter? J Clin Oncol 30:575-576
17. Hoefnagel LD, van de Vijver MJ, van Slooten HJ et al (2010) Receptor conversion in distant breast cancer metastases. Breast Cancer Res 12:R75
18. Duchnowska R, Dziadziuszko R, Trojanowski T et al (2012) Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res 14:R119
19. Niikura N, Liu J, Hayashi N et al (2010) Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30:593-599
20. Amir E, Miller N, Geddie W et al (2012) Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 30:587-592
21. Amir E, Clemons M, Purdie CA et al (2012) Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 38:708-714
22. Liedtke C, Broglio K, Moulder S et al (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20:1953-1958
23. Hoefnagel LD, Moelans CB, Meijer SL et al (2012) Prognostic value of estrogen receptor alpha and progesterone receptor conversion in distant breast cancer metastases. Cancer 118:4929-4935
24. Cardoso F, Costa A, Norton L et al (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21:242-252
25. Hammond ME, Hayes DF, Dowsett M et al (2010) American society of clinical oncology/college Of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795
26. Sanpaolo P, Barbieri V, Genovesi D (2011) Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Eur J Surg Oncol 37:876-882
27. Bauer K, Parise C, Caggiano V (2010) Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen consensus statement for early breast cancer. BMC Cancer 10:228-240